How many insider trades does FilingIQ track for GDTC?

FilingIQ tracks 3 Form 4 insider transactions for GDTC (CytoMed Therapeutics Ltd), covering filings from May 13, 2026 onwards. 3 of those were filed in the last 90 days.

Are GDTC insiders net buyers or net sellers?

Across the full Form 4 history for GDTC, 3 transactions (100%) were open-market purchases and 0 (0%) were open-market sales. Compensatory awards and option exercises are filtered out of these counts.

Where does GDTC insider data come from?

Every transaction shown on this page is sourced directly from SEC EDGAR Form 4 filings. FilingIQ parses the raw XML, normalises insider identity across reporting variations, and scores each trade on its multi-factor composite model.

What sector is GDTC in?

CytoMed Therapeutics Ltd (GDTC) is classified in the Healthcare sector, specifically Biotechnology, with a current market capitalisation of $12.19M.

GDTC insider trading

NasdaqCM Healthcare

CytoMed Therapeutics Ltd — scored insider trade history from SEC Form 4 filings, parsed and contextualised by FilingIQ.

Total Form 4 trades

Last 90 days

Buys / sells

100% / 0%

Market cap

$12.19M

About CytoMed Therapeutics Ltd

CytoMed Therapeutics Limited, a clinical stage biopharmaceutical company, focuses on developing novel cell-based immunotherapies for the treatment of human cancers and degenerative diseases in Malaysia and Singapore. The company's lead product candidate is CTM-N2D, an expanded gamma delta T cells grafted with natural killer group 2D ligands-targeting chimeric antigen receptor, which is in Phase I clinical trials comprising to improve anti-cancer cytotoxicity. It is also developing iPSC-gdNKT, a pluripotent stem cell-derived gamma delta natural killer T cells platform for cancer treatment; CTM-GDT, a product candidate that consists of expanded allogeneic gamma delta T cells and exploits the potential of the cells to recognize and treat a broad range of cancers; and CTM-MSC, an injectable allogeneic umbilical cord-derived mesenchymal stem cells for cartilage injury. It has research collaboration agreement with Sengkang General Hospital to provide CTM-MSC and its conditioned media for in vivo studies and Phase I clinical trial in Singapore; and Business and Research Collaboration Agreement with SunAct Cancer Institute Private Limited to conduct clinical trials for the GMP grade CTM-GDT. CytoMed Therapeutics Limited was incorporated in 2018 and is headquartered in Singapore.

Company website: w2.cytomed.sg

GDTC insider activity at a glance

FilingIQ has scored 3 insider transactions for GDTC since May 13, 2026. The most recent filing in our index is dated Jul 20, 2026.

Across the full history, 3 open-market purchases and 0 open-market sales were filed under transaction codes P and S respectively. Compensatory share awards (code A) and option exercises (code M) are tracked separately and not counted here.

The average FilingIQ composite score on GDTC insider trades is 58.0/100, produced by FilingIQ's multi-factor Form 4 model. Model framework documented at methodology.

View live GDTC trades on FilingIQ Raw filings on SEC EDGAR

Other Healthcare tickers with recent insider activity

UTHR 1,082

UNITED THERAPEUTICS Corp

APLS 272

Apellis Pharmaceuticals, Inc.

NUVL 218

Nuvalent, Inc.

KYMR 203

Kymera Therapeutics, Inc.

GH 191

Guardant Health, Inc.

Frequently asked

How many insider trades does FilingIQ track for GDTC?: FilingIQ tracks 3 Form 4 insider transactions for GDTC (CytoMed Therapeutics Ltd), covering filings from May 13, 2026 onwards. 3 of those were filed in the last 90 days.
Are GDTC insiders net buyers or net sellers?: Across the full Form 4 history for GDTC, 3 transactions (100%) were open-market purchases and 0 (0%) were open-market sales. Compensatory awards and option exercises are filtered out of these counts.
Where does GDTC insider data come from?: Every transaction shown on this page is sourced directly from SEC EDGAR Form 4 filings. FilingIQ parses the raw XML, normalises insider identity across reporting variations, and scores each trade on its multi-factor composite model.
What sector is GDTC in?: CytoMed Therapeutics Ltd (GDTC) is classified in the Healthcare sector, specifically Biotechnology, with a current market capitalisation of $12.19M.

Methodology & sources

Every GDTC insider transaction shown on FilingIQ is parsed directly from a public SEC Form 4 XML filing. Insider identity is normalised across reporting variants (CIK changes, name spellings, related-party indirect holdings). The FilingIQ composite score is documented in full on the team page and algo disclosure. Not investment advice; see disclaimer.